Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of Potent and Selective Blockers Targeting the Epilepsy-Associated KNa1.1 Channel.

Journal of medicinal chemistry - 14 Nov 2024

Zheng Ruqiu, Li Zhongtang, Wang Qiufeng, Liu Shiqi, Liu Ningfeng, Li Yiyan, Zhu Guiwang, Liu Zhenming, Huang Zhuo, Zhang Liangren

Abstract excerpt

Gain-of-function (GOF) mutations of the sodium-activated potassium channel KNa1.1 (Slack, Slo2.2, or KCa4.1) induce severe, drug-resistant forms of epilepsy in infants and children. Although quinidine has shown promise in treating KCNT1-related epilepsies compared to other drugs, its limited efficacy and substantial side effects necessitate the development of new KNa1.1 channel inhibitors. In this study, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to Drug Discovery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epilepsy

Share to HEK293 Cells

Share to Potassium Channel Blockers

Share to Potassium Channels, Sodium-Activated

Share to Rats, Sprague-Dawley

Share to Structure-Activity Relationship

Source

Identifiers

PMID: 39445572
DOI: 10.1021/acs.jmedchem.4c01815

Genes

KCNT1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of Potent and Selective Blockers Targeting the Epilepsy-Associated KNa1.1 Channel.PMID 39445572Read ↗

Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole SeriesSemantic proximity Read ↗

New use for an old drug: quinidine in KCNT1-related epilepsy therapy.Semantic proximity Read ↗

Large-Scale Structure-Based Virtual Screening Identifies Diverse K <sub>Na</sub> 1.1 (KCNT1) Potassium Channel InhibitorsSemantic proximity Read ↗

Targeting KNa1.1 channels in KCNT1-associated epilepsy.Semantic proximity Read ↗

Approaches for the discovery of drugs that target K Na 1.1 channels in KCNT1-associated epilepsy.Semantic proximity Read ↗

Electrophysiological characterization of human KCNT1 channel modulators and the therapeutic potential of hydroquinine and tipepidine in KCNT1 mutation-associated epilepsy mouse model.Semantic proximity Read ↗

Identification of new KCNT1-epilepsy drugs by <i>in silico,</i> cell and <i>Drosophila</i> modellingSemantic proximity Read ↗

Quinidine Therapy for Lennox-Gastaut Syndrome With KCNT1 Mutation. A Case Report and Literature ReviewSemantic proximity Read ↗

Isoform-Selective KCNA1 Potassium Channel Openers Built from Glycine.Semantic proximity Read ↗

A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy.Semantic proximity Read ↗

Structure-based identification and characterisation of novel inhibitors of K <sub>Na</sub> 1.1 potassium channels, a stratified target for <i>KCNT1</i> -related epilepsySemantic proximity Read ↗

Overcoming challenges of HERG potassium channel liability through rational design: Eag1 inhibitors for cancer treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.